- Home
- CHPT vs DRTS Comparison
CHPT vs DRTS Comparison
Compare CHPT & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHPT
- DRTS
- Stock Information
- Founded
- CHPT 2007
- DRTS 2015
- Country
- CHPT United States
- DRTS Israel
- Employees
- CHPT N/A
- DRTS N/A
- Industry
- CHPT Industrial Specialties
- DRTS Medical/Dental Instruments
- Sector
- CHPT Consumer Discretionary
- DRTS Health Care
- Exchange
- CHPT Nasdaq
- DRTS Nasdaq
- Market Cap
- CHPT 256.9M
- DRTS 300.2M
- IPO Year
- CHPT N/A
- DRTS N/A
- Fundamental
- Price
- CHPT $11.08
- DRTS $4.20
- Analyst Decision
- CHPT Hold
- DRTS Strong Buy
- Analyst Count
- CHPT 11
- DRTS 1
- Target Price
- CHPT $18.40
- DRTS $9.00
- AVG Volume (30 Days)
- CHPT 478.3K
- DRTS 60.0K
- Earning Date
- CHPT 12-03-2025
- DRTS 11-18-2025
- Dividend Yield
- CHPT N/A
- DRTS N/A
- EPS Growth
- CHPT N/A
- DRTS N/A
- EPS
- CHPT N/A
- DRTS N/A
- Revenue
- CHPT $397,731,000.00
- DRTS N/A
- Revenue This Year
- CHPT N/A
- DRTS N/A
- Revenue Next Year
- CHPT $12.63
- DRTS N/A
- P/E Ratio
- CHPT N/A
- DRTS N/A
- Revenue Growth
- CHPT N/A
- DRTS N/A
- 52 Week Low
- CHPT $8.55
- DRTS $2.14
- 52 Week High
- CHPT $30.00
- DRTS $4.69
- Technical
- Relative Strength Index (RSI)
- CHPT 49.94
- DRTS 56.64
- Support Level
- CHPT $10.48
- DRTS $3.97
- Resistance Level
- CHPT $11.35
- DRTS $4.34
- Average True Range (ATR)
- CHPT 0.68
- DRTS 0.28
- MACD
- CHPT -0.15
- DRTS -0.01
- Stochastic Oscillator
- CHPT 30.10
- DRTS 64.29
About CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.